2,870 Shares of Medpace Holdings, Inc. $MEDP Bought by Cantor Fitzgerald Investment Advisors L.P.

Key Points

• Cantor Fitzgerald Investment Advisors initiated a position in Medpace, buying 2,870 shares worth approximately $1.79 million during the third quarter. Institutional investors collectively own 77.98% of the company.
• Medpace exceeded third-quarter expectations, reporting EPS of $4.84 versus the $4.44 consensus and revenue of $716 million, up 8.5% year over year.
• The stock opened at $653.96, near its 52-week high, while analysts maintained a consensus “Hold” rating with an average price target of $607.73; insiders have sold roughly $208 million of shares over the past 90 days.

Cantor Fitzgerald Investment Advisors L.P. bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,870 shares of the company's stock, valued at approximately $1,791,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. BlackRock Inc. bought a new stake in Medpace during the 2nd quarter valued at $1,323,047,000. State Street Corp lifted its position in shares of Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company's stock worth $376,483,000 after acquiring an additional 28,666 shares in the last quarter. Wasatch Advisors LP boosted its holdings in shares of Medpace by 19.4% in the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock worth $371,634,000 after acquiring an additional 125,625 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after acquiring an additional 38,760 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Medpace by 5.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company's stock valued at $190,044,000 after purchasing an additional 20,736 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ MEDP opened at $653.96 on Friday. The company's 50 day simple moving average is $609.84 and its two-hundred day simple moving average is $536.74. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $684.52. The stock has a market capitalization of $18.25 billion, a PE ratio of 36.72, a P/E/G ratio of 2.96 and a beta of 1.18.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating analysts' consensus estimates of $4.44 by $0.40. Medpace had a net margin of 18.24% and a return on equity of 104.17%. The firm had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. During the same period in the previous year, the business earned $3.86 EPS. The business's revenue for the quarter was up 8.5% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling at Medpace

In related news, CEO August Troendle sold 21,966 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares in the company, valued at approximately $211,549,590.75. This represents a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders sold 336,140 shares of company stock valued at $208,008,328. Company insiders own 20.50% of the company's stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of analyst reports. TD Cowen boosted their price objective on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. UBS Group started coverage on Medpace in a report on Wednesday, September 30th. They set a "neutral" rating and a $673.00 price objective on the stock. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a research note on Monday, September 14th. Weiss Ratings raised Medpace from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Finally, Robert W. Baird lifted their target price on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $607.73.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Third-quarter earnings beat expectations. Medpace reported adjusted EPS of $4.84, ahead of the roughly $4.44–$4.45 consensus, while revenue of $716 million modestly exceeded estimates. EPS rose from $3.86 a year earlier, and revenue increased 8.5%. Medpace Q3 earnings and revenues beat estimates
• Positive Sentiment: Profitability improved. Reports attributed the earnings beat in part to margin expansion, reinforcing the company’s operating leverage and supporting the view that there were few weaknesses in the quarterly report. Medpace Q3 2026 earnings and margin expansion
• Positive Sentiment: Management issued a favorable 2026 outlook. Medpace forecast EPS of $17.97 to $18.32, described as above Wall Street expectations, providing investors with continued earnings visibility. Medpace 2026 EPS forecast
• Positive Sentiment: A new $1 billion share-repurchase authorization replaced the prior program. The buyback signals management confidence and could support EPS and the share price by reducing the number of shares outstanding. Medpace receives $1 billion buyback authorization
• Negative Sentiment: The initial reaction was muted despite the beat. Investors may have been looking for a larger upside surprise, while Medpace’s high valuation—around 38 times earnings—leaves limited room for disappointment. Medpace slips despite third-quarter beat

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.